Disopyramide Antibody (001): sc-66033

Disopyramide Antibody (001) is a mouse monoclonal IgG1 antibody that detects Disopyramide protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). Anti-Disopyramide antibody (001) is available as a non-conjugated isotype antibody. Disopyramide is a Class IA antiarrhythmic medication that plays a crucial role in managing ventricular and supraventricular arrhythmias, particularly in patients recovering from heart attacks. Disopyramide′s mechanism of action involves stabilizing irregular heartbeats by directly interfering with cardiac membrane depolarization, essential for maintaining regular heart rhythm. Disopyramide shortens sinus node recovery time and lengthens atrial effective refractory period, while having minimal impact on atrioventricular node effective refractory period. This unique profile enables effective arrhythmia management without significantly affecting adrenergic receptors. Disopyramide exhibits depressant effects on the heart similar to guanidine and possesses anticholinergic and local anesthetic properties, making Disopyramide a versatile option in arrhythmia treatment. Side effects may include dizziness, fainting, dry mouth, palpitations, shortness of breath, and unusual fatigue.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Disopyramide Antibody (001) References:

1. Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model.  |  Yoshida, H., et al. 2002. Circ J. 66: 857-62. PMID: 12224826
2. Antiarrhythmic drug therapy of atrial fibrillation.  |  VerNooy, RA. and Mounsey, JP. 2004. Cardiol Clin. 22: 21-34. PMID: 14994845
3. Atrial fibrillation: rate control often better than rhythm control.  |  . 2004. Prescrire Int. 13: 64-9. PMID: 15148984
4. Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide.  |  Sugao, M., et al. 2005. J Cardiovasc Pharmacol. 45: 545-9. PMID: 15897781
5. Deglutition-induced atrial fibrillation.  |  Malik, A., et al. 2005. Tex Heart Inst J. 32: 602-4. PMID: 16429915
6. In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data.  |  Le Corre, P., et al. 1991. Chirality. 3: 405-11. PMID: 1756095
7. Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.  |  Nelson, WL., et al. 1981. J Med Chem. 24: 614-7. PMID: 7241519
8. Enantiomer separation of disopyramide with capillary electrophoresis using various cyclodextrins.  |  Juvancz, Z., et al. 1997. Electrophoresis. 18: 1002-6. PMID: 9221890